Economic impact of a rotavirus vaccine in Brazil

Journal of Health, Population and Nutrition

Volumn 26, Issue 4, 2008, Pages 388-396

  Constenla, Dagna O ^a   Linhares, Alexandre C ^b   Rheingans, Richard D ^a   Antil, Lynn R ^a   Waldman, Eliseu A ^c   da Silva, Luiz J ^d  

^a EMORY UNIVERSITY   (United States)

^b INSTITUTO EVANDRO CHAGAS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Brazil; Costs and cost analysis; Diarrhoea; Gastroenteritis; Infatile; Morbidity; Rotavirus; Rotavirus vaccines; Vaccination

Indexed keywords

ROTAVIRUS;

ROTAVIRUS VACCINE;

ARTICLE; BRAZIL; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DRUG EFFECT; ECONOMICS; FEMALE; GASTROENTERITIS; HUMAN; INFANT; MALE; PRESCHOOL CHILD; ROTAVIRUS; STATISTICS; VIRUS INFECTION;

BRAZIL; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; GASTROENTERITIS; HUMANS; INFANT; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 59449088886     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bresee JS, Glass RI, Ivanoff B, Gentsch JR. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999;17:2207-22.
2. Kapikian AZ, Hoshino Y, Chanok RM. R Ves. In: Knipe DM, Howley PM, editors. Fields virology, v. 1. 4th ed. Philadelphia: Lippincott, 2001:1787-834.
3. Victora C, Barros F. Diarrheal disease among children under five years in the Americas, 1980-11992. New York, NY: United Nations Children's Fund, 1993. 230 p.
4. Brasil. Ministério da Saúde. Departamento de Análise de Situação de Saúde/SVS. Indicadores de dados básicos para a saúde. Brasilia, D.F.: Ministério da Saúde, 2004. 280 p.
5. Benício MHD e Monteiro CA. Tendência secular da doença diarreica na infância nsa cidades de São Paulo (1984-1996). Rev Saúde Pública 2000;34(Suppl 6):S83-90.
6. Instituto Nacional de Alimentação e Nutrição. II pesquisa estadual de saúde e nutrição: saúde, nutrição, alimentação e condições socioeconômicas no estado de pernambuco. Brasilia, D.F.: Ministério da Saúde, 1998. 189 p.
7. Brasil. Ministério da Saúde. Departamento de Análise de Situação de Saúde/SVS. Sistema de informação sobre mortalidade. Brasilia, D.F.: Ministério da Saúde, 2004. 460 p.
8. Linhares AC, Bresee JS. Rotavirus vaccines and vaccination in Latin America. Rev Panam Salud Publica 2000;88:305-31.
9. Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007;21:205-16.
10. Rheingans RD, Constenla D, Antil L, Innis B, Breuer T. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007;21:192-204.
11. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996. 456 p.
12. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press, 1996. 1,022 p.
13. Pan-American Health Organization. Health analysis and Information systems area. Regional core health data initiative; technical health information system. Washington, DC: Pan-American Health Organization, 2004. 18 p. (http://wwww.paho.org/English/SHA/coredata/tabulator/ newTabulator.htm, accessed on 4 September 2003).
14. Barraza P, Avendaño LF, Spencer E, Calderón A, Prenzel I, Duarte E. Hospital infection caused by rotaviruses in infants, Santiago, Chile. Bol Oficina Sanit Panam 1986;101:328-38.
15. Bok K, Castagnaro NC, Diaz NE, Borsa A, Cagnoli MR, Nates S et al. Rotavirus laboratory network: results after one year of observation. Rev Argent Microbiol 999;31:1-12.
16. Bok K, Castagnaro N, Borsa A, Nates S, Espul C, Fay O et al. Surveillance for rotavirus in Argentina. J Med Virol 2001; 65:190-8.
17. Cardoso DDP, Soares CMA, Dias e Souza MB, de Azevedo Mda S, Martins RM, Queirâz DA et al. Epidemiological features of rotavirus infection in Goiania, Goias, Brazil, from 1986 to 2000. Mem Inst Oswaldo Cruz 2003;98:25-9.
18. Gomez JA A, Sordo ME, Gentile A. Epidemiologic patterns of diarrheal disease in Argentina: estimation of rotavirus disease burden. Pediatr Infect Dis J 2002;21:843-50.
19. González FS, Sordo ME, Rowensztein G, Sabbag L, Roussos A, De Petre E et al. Rotavirus diarrhea. Impact in a pediatric hospital of Buenos Aires. Medicina (B Aires) 1999;59:321-6.
20. Pérez-Schael I, González R, Fernández R, Alfonzo E, Inaty D, Boher Y et al. Epidemiological features of rotavirus infection in Caracas, Venezuela: implications for rotavirus immunization programs. J Med Virol 1999;59:520-6.
21. Urrestarazu MI, Liprandi F, Pérez de Suárez E, González R, Pérez-Schael I. Etiologic, clinical, and socio-demographic characteristics of acute diarrhea in Venezuela. Rev Panam Salud Publica 1999;6:149-56.
22. Velázquez FR, Matson DO, Guerrero ML, Shults J, Calve JJ, Morrow AL et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000;182:1602-9.
23. Villa S, Guiscafré H, Martínez H, Muñoz O, Gutiérrez G. Seasonal diarrhoeal mortality among Mexican children. Bull world Health Organ 1999;77:375-80.
24. Lopez AD, Salomon J, Ahmad O, Murray CJL, Mafat D. Life tables for 191 countries: data, methods and results. Geneva: World Health Organization, 2000. 254 p. (GPE discussion paper no. 9).
25. Baltussen R, Adam T, Tan Torres T, Hutubessy R, Acharya A, Evans D et al. Generalized cost effectiveness analysis: a guide. Geneva: World Health Organization, 2002. 329 p.
26. Liddle JL, Burgess MA, Gilbert GL, Hanson RM, McIntyre PB, Bishop RF et al. Rotavirus gastroenteritis: impact on young children, their families, and the health are system. Med J Aust 1997;167:304-7.
27. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
28. Salinas B, Pérez-Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants. Ped Infect Dis J 2005;24:807-16.
29. World Health Organization. WHO & UNICEF estimates of national immunization coverage, 2003. 10 p. (hhttp:////www.who.int/ vaccinessurveillance/WHOUNICEF_CoverageReview/, accessed on 11 October 2004).
30. Brenzel L, Claquin P. Immunization programs and their costs. Soc Sci Med 1994;39:527-36.
31. Miller MA, McCann L. Policy analysis of the use of hepatitis B, haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2004;9:19-35.
32. Walker D, Mosqueira NR, Penny ME, Lanata CF, Clark AD, Sanderson CF et al. Variation in the costs of delivering routine immunization services in Peru. Bull World Health Organ 2004;82:676-82.
33. Waters HR, Dougherty L, Tegang SP, Tran N, Wiysonge CS, Long K et al. Coverage and costs of childhood immunizations in Cameroon. Bull World Health Organ 2004;82:668-75.
34. Constenla D, O'Ryan M, Navarrete MS, Antil L, Rheingans RD. Potential cost effectiveness of a RV vaccine in Chile. Rev Méd Chile 2006;134:679-88.
35. Constenla D, Pérez-Schael I, Rheingans RD, Antil L, Salas H, Yarzábal JP. Evaluación del impacto económico de la vacuna antirrotavírica en Venezuela. [Assessment of the economic impact of the antiretroviral vaccine in Venezuela]. Rev Panam Salud Pública 2006;20:213-22 [Spanish].
36. World Health Organization. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva: World Health Organization, 2001. 210 p.
37. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007;369:389-96.
38. Constenla D. Evaluating the cost-effectiveness of a pneumococcal conjugate vaccination program in selected Latin American countries. Rev Panam Salud Publica 2008 (in press).
39. Constenla D, Ortega-Barría E, Rheingans R, Antil L, Sáez-Llorens X. Impacto económico de la vacuna antirrotavirica en Panamá [Economic impact of rotavirus vaccination in Panama]. An Pediat (Barc) 2008;68:128-35 [Spanish].
40. Constenla D, Rivera M, Rheingans RD, Antil L, Vásquez ML. Evaluación económica de una eventual incorporación de la vacuna anti-rotavirus en el calendario de vacunación infantil en Honduras. Rev Med Hond 2006;74:19-29.
41. Dayan GH, Nguyen VH, Debbag R, Gómez R, Wood SC. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001;19:4204-13.